NO20042697L - Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist - Google Patents
Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonistInfo
- Publication number
- NO20042697L NO20042697L NO20042697A NO20042697A NO20042697L NO 20042697 L NO20042697 L NO 20042697L NO 20042697 A NO20042697 A NO 20042697A NO 20042697 A NO20042697 A NO 20042697A NO 20042697 L NO20042697 L NO 20042697L
- Authority
- NO
- Norway
- Prior art keywords
- antagonist
- toll
- tumor
- methods
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33343401P | 2001-11-27 | 2001-11-27 | |
| PCT/US2002/038098 WO2003045431A2 (en) | 2001-11-27 | 2002-11-26 | Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042697L true NO20042697L (no) | 2004-06-25 |
Family
ID=23302758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042697A NO20042697L (no) | 2001-11-27 | 2004-06-25 | Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20030138413A1 (enExample) |
| EP (1) | EP1450858A2 (enExample) |
| JP (3) | JP2006502080A (enExample) |
| CN (1) | CN1617742B (enExample) |
| AU (1) | AU2002359516B2 (enExample) |
| BR (1) | BR0214457A (enExample) |
| CA (1) | CA2468320A1 (enExample) |
| HU (1) | HUP0500999A2 (enExample) |
| MX (1) | MXPA04004998A (enExample) |
| NO (1) | NO20042697L (enExample) |
| NZ (1) | NZ565420A (enExample) |
| TW (1) | TW200303759A (enExample) |
| WO (1) | WO2003045431A2 (enExample) |
| ZA (1) | ZA200404113B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE335510T1 (de) * | 1998-05-22 | 2006-09-15 | Ottawa Health Research Inst | Methoden und produkte zur induzierung mukosaler immunität |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| AU2001227889A1 (en) | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
| US20040175355A1 (en) * | 2001-04-18 | 2004-09-09 | The Regents Of The University Of California | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
| EP2572715A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| CA2516028C (en) * | 2003-02-14 | 2012-10-16 | University Of Southern California | Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| JP5022028B2 (ja) | 2003-03-26 | 2012-09-12 | サイトス・バイオテクノロジー・アクチェンゲゼルシャフト | メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート |
| EP1646427A1 (en) * | 2003-07-22 | 2006-04-19 | Cytos Biotechnology AG | Cpg-packaged liposomes |
| EP3476861A1 (en) | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
| TW200533750A (en) * | 2004-02-19 | 2005-10-16 | Coley Pharm Group Inc | Immunostimulatory viral RNA oligonucleotides |
| US7868158B2 (en) * | 2004-07-19 | 2011-01-11 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| US20060147456A1 (en) * | 2004-07-20 | 2006-07-06 | Serge Lebecque | Induction of apoptosis in toll-like receptor expressing tumor cells |
| US20080274140A1 (en) * | 2004-11-19 | 2008-11-06 | David B Weiner | Vaccines and Methods for Using the Same |
| EP1834650A1 (en) * | 2004-12-28 | 2007-09-19 | ImmunoFrontier, Inc. | Cancer vaccine preparation |
| EP1712241A1 (en) * | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| US20100143899A1 (en) * | 2005-05-17 | 2010-06-10 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
| CN101501055B (zh) * | 2005-06-23 | 2016-05-11 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
| BRPI0613515A2 (pt) * | 2005-07-11 | 2011-01-11 | Cbio Ltd | imunomodulação induzida por chaperonina 10 |
| US20100003287A1 (en) * | 2005-12-01 | 2010-01-07 | The Provost, Fellows And Scholars Of The Coll. Of The Holy And Undivided Trinity Of Queen Elizabeth | Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases |
| EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| WO2008073959A2 (en) * | 2006-12-12 | 2008-06-19 | Idera Pharmaceuticals, Inc. | Synthetic agonists of tlr9 |
| US8445442B2 (en) * | 2007-04-26 | 2013-05-21 | University Of Vermont And State Agricultural College | CCL18 and CCL3 methods and compositions for detecting and treating cancer |
| EP2222344A4 (en) * | 2007-11-30 | 2012-11-07 | Baylor College Medicine | VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE |
| BRPI1008063A2 (pt) * | 2009-01-30 | 2015-08-25 | Idera Pharmaceuticals Inc | Agonistas sinteticas de tlr9 |
| KR101853702B1 (ko) | 2009-12-07 | 2018-05-03 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 항-종양 항체 치료를 향상시키는 방법 |
| US20120309691A1 (en) * | 2010-02-04 | 2012-12-06 | Dapeng Zhou | Tumor targeted delivery of immunomodulators by nanopolymers |
| EP2531207B1 (en) * | 2010-02-05 | 2019-10-30 | Cornell University | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| CA2805989A1 (en) | 2010-07-19 | 2012-01-26 | Yeda Research And Development Co. Ltd. | Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases |
| TWI506035B (zh) * | 2010-08-13 | 2015-11-01 | Baylor Res Inst | 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑 |
| AU2013271375B2 (en) * | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| SG11201510552WA (en) * | 2012-06-27 | 2016-01-28 | Hasumi Internat Res Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
| BR112015004501B1 (pt) | 2012-09-05 | 2021-04-13 | Chugai Seiyaku Kabushiki Kaisha | Derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo e composição farmacêutica que o compreende |
| CN103768604B (zh) * | 2012-10-24 | 2016-03-30 | 北京圣沃德生物科技有限公司 | 治疗性肿瘤疫苗 |
| AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CN103013915B (zh) * | 2013-01-09 | 2014-05-28 | 高岱清 | 一种高活性负载抗原的树突状细胞的制备方法 |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| AU2016259020B2 (en) * | 2015-05-07 | 2021-12-09 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| ES2987696T3 (es) * | 2015-05-29 | 2024-11-15 | Dynavax Tech Corp | Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| BR112017025533A2 (pt) * | 2015-05-29 | 2018-08-07 | Dynavax Tech Corp | método para tratar câncer em um paciente humano |
| TW201716084A (zh) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| EP3331612A4 (en) * | 2015-08-06 | 2019-07-03 | Memorial Sloan Kettering Cancer Center | METHOD AND COMPOSITIONS FOR TUMOR THERAPY |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| WO2017192470A1 (en) * | 2016-05-03 | 2017-11-09 | Merck Sharp & Dohme Corp. | Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides |
| WO2017214706A1 (en) * | 2016-06-15 | 2017-12-21 | Tissue Regeneration Therapeutics Inc. | Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc) |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018060513A1 (en) | 2016-09-30 | 2018-04-05 | Galderma Research & Development | Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists |
| WO2018060514A1 (en) | 2016-09-30 | 2018-04-05 | Galderma Research & Development | Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| EP3582793A4 (en) * | 2017-02-17 | 2020-12-16 | Aivita Biomedical, Inc. | METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS |
| EP3635410A4 (en) * | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| CN112912389B (zh) * | 2018-06-19 | 2024-04-19 | H·李·莫菲特癌症中心和研究所公司 | 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗 |
| CN113005090A (zh) * | 2019-12-20 | 2021-06-22 | 上海细胞治疗集团有限公司 | 共表达趋化因子和共刺激分子的dc细胞及其应用 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230210968A1 (en) * | 2020-06-11 | 2023-07-06 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63503308A (ja) * | 1986-05-09 | 1988-12-02 | スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ | 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 |
| US5840708A (en) * | 1992-12-14 | 1998-11-24 | Allegheny University Of The Health Sciences | Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of Neurological pathologies |
| AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| EP0772619B2 (en) * | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6071535A (en) * | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| ATE292980T1 (de) * | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| ES2284247T3 (es) * | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| TR200103018T2 (tr) * | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| WO2001062275A1 (en) * | 2000-02-24 | 2001-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
| EP1283722A1 (en) * | 2000-03-31 | 2003-02-19 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
-
2002
- 2002-11-25 TW TW091134176A patent/TW200303759A/zh unknown
- 2002-11-26 NZ NZ565420A patent/NZ565420A/en not_active IP Right Cessation
- 2002-11-26 WO PCT/US2002/038098 patent/WO2003045431A2/en not_active Ceased
- 2002-11-26 HU HU0500999A patent/HUP0500999A2/hu unknown
- 2002-11-26 JP JP2003546932A patent/JP2006502080A/ja active Pending
- 2002-11-26 MX MXPA04004998A patent/MXPA04004998A/es unknown
- 2002-11-26 AU AU2002359516A patent/AU2002359516B2/en not_active Ceased
- 2002-11-26 CA CA002468320A patent/CA2468320A1/en not_active Abandoned
- 2002-11-26 EP EP02794058A patent/EP1450858A2/en not_active Withdrawn
- 2002-11-26 BR BRPI0214457-3A patent/BR0214457A/pt not_active IP Right Cessation
- 2002-11-26 CN CN028275985A patent/CN1617742B/zh not_active Expired - Fee Related
- 2002-11-26 US US10/304,616 patent/US20030138413A1/en not_active Abandoned
-
2004
- 2004-05-26 ZA ZA200404113A patent/ZA200404113B/xx unknown
- 2004-06-25 NO NO20042697A patent/NO20042697L/no not_active Application Discontinuation
-
2005
- 2005-11-18 JP JP2005334633A patent/JP2006131638A/ja active Pending
-
2008
- 2008-09-19 US US12/234,361 patent/US20090087440A1/en not_active Abandoned
-
2009
- 2009-12-01 JP JP2009274004A patent/JP2010053140A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500999A2 (en) | 2007-11-28 |
| TW200303759A (en) | 2003-09-16 |
| JP2006502080A (ja) | 2006-01-19 |
| BR0214457A (pt) | 2006-11-21 |
| JP2010053140A (ja) | 2010-03-11 |
| WO2003045431A2 (en) | 2003-06-05 |
| EP1450858A2 (en) | 2004-09-01 |
| AU2002359516B2 (en) | 2006-02-02 |
| US20090087440A1 (en) | 2009-04-02 |
| CN1617742B (zh) | 2010-10-27 |
| AU2002359516A1 (en) | 2003-06-10 |
| ZA200404113B (en) | 2006-03-29 |
| WO2003045431A3 (en) | 2004-01-22 |
| JP2006131638A (ja) | 2006-05-25 |
| US20030138413A1 (en) | 2003-07-24 |
| NZ565420A (en) | 2009-09-25 |
| CA2468320A1 (en) | 2003-06-05 |
| CN1617742A (zh) | 2005-05-18 |
| MXPA04004998A (es) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042697L (no) | Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist | |
| DK2283867T3 (da) | Fremgangsmåder til behandling ved anvendelse af anti-ErbB antistof-maytansinoidkonjugater | |
| NO20033995L (no) | Fremgangsmate ved frakturering av en underjordisk formasjon | |
| DE60040956D1 (de) | Riss- und splitterbeständiger Bohrlochzement | |
| IL166625A0 (en) | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer | |
| DK3342411T3 (da) | Rapamycinderivat til behandling af pancreascancer | |
| NO20031489D0 (no) | Fremgangsmåte og anordning ved trekkbar broplugg | |
| PL363339A1 (en) | Method of checking ballast profile | |
| NO20033684L (no) | Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater | |
| NO20032966D0 (no) | Fremgangsmåte og anordning ved utboring av sementplugger | |
| NO20033429L (no) | Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) | |
| AU2002317105A1 (en) | Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors | |
| EP1390052A4 (en) | INHIBITION OF JUN KINASE | |
| PL1781321T3 (pl) | Sposób leczenia raka zawierający antagonistę VEGF-B | |
| AU2002308522A8 (en) | Methods for inhibiting tumor cell proliferation | |
| AU2003231084A8 (en) | Identification of biomarkers for detecting prostate cancer | |
| GB0201504D0 (en) | Method of payment | |
| IS7438A (is) | Lyfjablanda úr PDE4 eða PDE3/4 tálma og histamínviðtakamótlyfi | |
| EP1534317A4 (en) | N-TERMINAL TRONQUEE GALECTIN-3 AND ANTIBODIES FOR THE TREATMENT OF CANCER | |
| GB0101686D0 (en) | Cyclin dependent kinase inhibitors | |
| EP1378752A4 (en) | METHOD FOR QUANTIFYING ANTIGEN EXPRESSION | |
| EP1531803A4 (en) | METHOD OF INHIBITING THE PROLIFERATION OF CANCER CELLS | |
| GB0124272D0 (en) | Method of delivering money | |
| NO20010803L (no) | Fremgangsmate ved alkylering og nye hydroksyfenylbenztriazoler | |
| NO20006537D0 (no) | Fremgangsmåte og anordning ved bunndetektor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |